AR114533A1 - Oligonucleótidos antisentido de metaloproteinasa-1 de matriz - Google Patents
Oligonucleótidos antisentido de metaloproteinasa-1 de matrizInfo
- Publication number
- AR114533A1 AR114533A1 ARP190101321A ARP190101321A AR114533A1 AR 114533 A1 AR114533 A1 AR 114533A1 AR P190101321 A ARP190101321 A AR P190101321A AR P190101321 A ARP190101321 A AR P190101321A AR 114533 A1 AR114533 A1 AR 114533A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- human mmp
- mrna
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un método para tratar enfermedades o afecciones asociadas con la transcripción del gen de MMP-1 humana que implica la administración del derivado de ácido nucleico peptídico de acuerdo con la reivindicación 1 a un sujeto. La presente proporciona el derivado de ácido nucleico peptídico de acuerdo con la reivindicación 1, que se dirige al sitio de empalme 5 del pre-ARNm de MMP-1 humana exón 5. Los derivados de ácido nucleico peptídicos en la presente inducen fuertemente variantes de corte y empalme del ARNm de MMP-1 humana en células y son muy útiles para tratar afecciones o enfermedades de envejecimiento de la piel asociadas con la proteína MMP-1 humana. Reivindicación 1: Un derivado de ácido nucleico peptídico representado por la fórmula (1), o una sal farmacéuticamente aceptable del mismo, en donde, n es un número entero entre 10 y 21; el compuesto de fórmula (1) posee al menos una superposición complementaria de 10 mer con la secuencia de pre-ARNm de 16 mer de [(5®3) CAUAUAUGGUGAGUAU] en el pre-ARNm de MMP-1 humana; el compuesto de fórmula (1) es completamente complementario al pre-ARNm de MMP-1 humana, o parcialmente complementario al pre-ARNm de MMP-1 humana con uno o dos emparejamientos erróneos; S₁, S₂, Sₙ₋₁, Sₙ, T₁, T₂, ···, Tₙ₋₁, y Tₙ representan independientemente radical hibrido, deuterio, alquilo sustituido o no sustituido, o arilo sustituido o no sustituido; X e Y representan independientemente radical hibrido, deuterio, formil [H-C(=O)-], aminocarbonil [NH₂-C(=O)-], aminotiocarbonil [NH₂-C(=S)-], alquilo sustituido o no sustituido, arilo sustituido o no sustituido, alquiloxi sustituido o no sustituido, ariloxi sustituido o no sustituido, alquilacilo sustituido o no sustituido, arilacilo sustituido o no sustituido, alquiloxicarbonilo sustituido o no sustituido, ariloxicarbonilo sustituido o no sustituido, alquilaminocarbonilo sustituido o no sustituido, arilaminocarbonilo sustituido o no sustituido, alquilaminotiocarbonilo sustituido o no sustituido, arilaminotiocarbonilo sustituido o no sustituido, alquiloxitiocarbonilo sustituido o no sustituido, ariloxitiocarbonilo sustituido o no sustituido, alquilsulfonilo sustituido o no sustituido, arilsulfonilo sustituido o no sustituido, alquilfosfonilo sustituido o no sustituido, o arilfosfonilo sustituido o no sustituido; Z representa radical hibrido, deuterio, hidroxi, alquiloxi sustituido o no sustituido, ariloxi sustituido o no sustituido, amino sustituido o no sustituido, alquilo sustituido o no sustituido, o arilo sustituido o no sustituido; B₁, B₂, ···, Bₙ₋₁, y Bₙ se seleccionan independientemente de nucleobases naturales que incluyen adenina, timina, guanina, citosina y uracilo, y nucleobases no naturales; y, al menos cuatro de B₁, B₂, ···, Bₙ₋₁, y Bₙ se seleccionan independientemente de nucleobases no naturales con un radical amino sustituido o no sustituido unido covalentemente al resto de nucleobase.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180057352 | 2018-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR114533A1 true AR114533A1 (es) | 2020-09-16 |
Family
ID=68540475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190101321A AR114533A1 (es) | 2018-05-18 | 2019-05-17 | Oligonucleótidos antisentido de metaloproteinasa-1 de matriz |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210292369A1 (es) |
EP (1) | EP3794124A4 (es) |
JP (1) | JP7422406B2 (es) |
KR (1) | KR102194594B1 (es) |
CN (1) | CN112041447A (es) |
AR (1) | AR114533A1 (es) |
AU (1) | AU2019268955A1 (es) |
BR (1) | BR112020017892A2 (es) |
CA (1) | CA3091911A1 (es) |
MX (1) | MX2020009836A (es) |
SG (1) | SG11202008247WA (es) |
TW (1) | TWI832851B (es) |
WO (1) | WO2019221570A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102304280B1 (ko) | 2018-08-14 | 2021-09-23 | 올리패스 주식회사 | 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5719262A (en) * | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US6617422B1 (en) * | 1997-05-23 | 2003-09-09 | Peter Nielsen | Peptide nucleic acid monomers and oligomers |
US20030105044A1 (en) * | 2001-10-17 | 2003-06-05 | Isis Pharmaceuticals Inc. | Antisense modulation of matrix metalloproteinase 1 expression |
AU2001250572A1 (en) * | 2000-04-07 | 2001-10-23 | Epigenomics Ag | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
DE10238298A1 (de) * | 2002-08-21 | 2004-03-04 | Beiersdorf Ag | Verwendung von Antisense-Oligonucleotiden zur Behandlung von degenerativen Hauterscheinungen |
US7579455B2 (en) * | 2003-09-29 | 2009-08-25 | Topigen Pharmaceutique Inc. | Oligonucleotide compositions and methods for treating disease including inflammatory conditions |
US7511025B2 (en) * | 2004-06-16 | 2009-03-31 | Trustees Of Dartmouth College | Compositions and methods for inhibiting the synthesis or expression of MMP-1 |
KR20090098710A (ko) * | 2008-03-14 | 2009-09-17 | 주식회사 씨티아이바이오 | 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체 |
KR20120073536A (ko) * | 2010-12-27 | 2012-07-05 | 주식회사 파나진 | 다중전하를 갖는 pna |
US20150240239A1 (en) * | 2014-02-27 | 2015-08-27 | Nugen Biosience (Taiwan) Co., Ltd. | Methods and pharmaceutical compositions for inhibiting matrix metalloproteinases 1 by interference ribonucleic acid |
WO2016037071A2 (en) * | 2014-09-05 | 2016-03-10 | Rxi Pharmaceuticals Corporation | Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1 |
JP7407592B2 (ja) * | 2016-08-08 | 2024-01-04 | オリパス コーポレーション | アンドロゲン受容体アンチセンスオリゴヌクレオチド |
EP3512870B1 (en) * | 2016-09-16 | 2022-08-03 | Olipass Corporation | Scn9a antisense oligonucleotides |
JP7089511B2 (ja) * | 2016-10-11 | 2022-06-22 | オリパス コーポレーション | HIF1-αアンチセンスオリゴヌクレオチド |
AU2017385962B2 (en) * | 2016-12-30 | 2021-09-02 | Olipass Corporation | Exon skipping by peptide nucleic acid derivatives |
-
2019
- 2019-04-02 TW TW108111655A patent/TWI832851B/zh active
- 2019-05-03 AU AU2019268955A patent/AU2019268955A1/en active Pending
- 2019-05-03 WO PCT/KR2019/005994 patent/WO2019221570A1/en active Application Filing
- 2019-05-03 CA CA3091911A patent/CA3091911A1/en active Pending
- 2019-05-03 US US17/055,809 patent/US20210292369A1/en active Pending
- 2019-05-03 MX MX2020009836A patent/MX2020009836A/es unknown
- 2019-05-03 SG SG11202008247WA patent/SG11202008247WA/en unknown
- 2019-05-03 BR BR112020017892-6A patent/BR112020017892A2/pt unknown
- 2019-05-03 EP EP19802852.4A patent/EP3794124A4/en active Pending
- 2019-05-03 JP JP2020564534A patent/JP7422406B2/ja active Active
- 2019-05-03 CN CN201980026668.4A patent/CN112041447A/zh active Pending
- 2019-05-10 KR KR1020190054681A patent/KR102194594B1/ko active IP Right Grant
- 2019-05-17 AR ARP190101321A patent/AR114533A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202002991A (zh) | 2020-01-16 |
JP7422406B2 (ja) | 2024-01-26 |
WO2019221570A1 (en) | 2019-11-21 |
TWI832851B (zh) | 2024-02-21 |
KR20190132220A (ko) | 2019-11-27 |
EP3794124A1 (en) | 2021-03-24 |
MX2020009836A (es) | 2021-01-08 |
US20210292369A1 (en) | 2021-09-23 |
KR102194594B1 (ko) | 2020-12-23 |
BR112020017892A2 (pt) | 2020-12-22 |
JP2021524236A (ja) | 2021-09-13 |
SG11202008247WA (en) | 2020-12-30 |
CA3091911A1 (en) | 2019-11-21 |
EP3794124A4 (en) | 2022-08-10 |
AU2019268955A1 (en) | 2020-11-26 |
CN112041447A (zh) | 2020-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017213503B2 (en) | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | |
ES2765463T3 (es) | Acido nucleico antisentido para usar en el tratamiento de la distrofia muscular de Duchenne | |
US20190092828A1 (en) | Alternative nucleic acid molecules containing reduced uracil content and uses thereof | |
ES2964695T3 (es) | Conjugados de oligonucleótidos peptídicos | |
US10385088B2 (en) | Polynucleotide molecules and uses thereof | |
AR109303A1 (es) | Oligonucleótidos antisentido del receptor de andrógenos | |
ES2737960T3 (es) | Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos | |
ES2834556T3 (es) | Lípidos y formulaciones de nanopartículas lipídicas novedosos para la entrega de ácidos nucleicos | |
Yan et al. | Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme | |
ES2748868T3 (es) | Acido nucleico antisentido | |
AU2019278884B2 (en) | Lipid-modified nucleic acid compounds and methods | |
JP2019526555A5 (es) | ||
EP3157573A2 (en) | Alternative nucleic acid molecules and uses thereof | |
CA2933568A1 (en) | Modified nucleic acid molecules and uses thereof | |
JP2015512254A (ja) | オリゴヌクレオチドアナログのボロン酸結合体 | |
AR114533A1 (es) | Oligonucleótidos antisentido de metaloproteinasa-1 de matriz | |
CA3176196A1 (en) | Bifunctional molecules and methods of using thereof | |
ES2958492T3 (es) | Glicolípidos y composiciones farmacéuticas de los mismos para uso en terapia | |
ES2901772T3 (es) | Conjugados de péptido oligonucleótido | |
US9670238B1 (en) | 5′-dibenzyl phosphates of 5-azacytidine or 2′-deoxy-5-azacytidine | |
AR110710A1 (es) | Oligonucléotidos antisentido snap25 | |
US20200123190A1 (en) | 5'-position dibenzyl monophosphate derivative of nucleoside-based anticancer agent or antivirus agent | |
US11572557B2 (en) | Photoreversible acylation reagents | |
ES2942575T3 (es) | Derivado de oligonucleótido o sal del mismo | |
US20140330004A1 (en) | Oligonucleotide |